acquires
Quantum Partners advised LARALAB GmbH and its shareholders exclusively in the M&A process
Andreas Brinkrolf has many years of corporate finance experience and has already founded several successful companies.
As Venture Manager and later as Managing Director of the Siemens Technology Accelerator, he was responsible for the external marketing of Siemens technologies through sales, spin-offs and licensing. The focus was on high-tech projects, e.g. in the fields of sensor technology, new materials and software.
As founder and CEO of Tiburon Partners AG, he invested in Internet and software companies and accompanied some of the companies through their entire life cycle to exit. He was responsible for the subsequent sale of Tiburon Partners AG to a listed holding company. Mr. Brinkrolf was a co-founder of Invoco Holding GmbH and helped it develop into one of the leading providers of outsourcing services in Germany. In 2013, he was responsible for the sale of the company to Xerox Corporation. In recent years, Mr. Brinkrolf has advised on over 50 transactions - initial investments, capital increases and sales.
He studied business administration at the Universities of Bamberg and Aston (UK) and completed his doctorate at the University of St. Gallen (CH).
Andreas Brinkrolf
Deal Partner
brinkrolf@quantum-partners.de
+49 89 414 144 355
Quantum Partners advises LARALAB GmbH and its shareholders on the sale to Abbott Laboratories
Treatment procedures for structural heart interventions have advanced enormously in recent years and are now a billion-dollar market. At the same time, complex manual preliminary tests and a fragmented software landscape are slowing down everyday clinical practice. Outdated desktop tools and manual workups result in considerable time losses per case. Negative initial assessments often delay decisions by days or weeks, increase the cost of treatment, and delay studies.
Laralab addresses precisely these bottlenecks: With heart.ai, the Munich-based software startup provides the first fully automated, cloud-based solution for the pre-screening of cardiac interventions, including automatic segmentation, 4D image analysis, and configurable workflows. For the first time, screening results are immediately available without manual workup, enabling significant efficiency gains in both treatments and clinical trials.
Following a structured international sales process, LARALAB has decided to merge with Abbott, one of the world’s leading providers in the field of structural heart disease. Abbott is thus expanding its range of products and services along the cardiovascular treatment pathway with leading digital technology and creating the basis for LARALAB to roll out heart.ai more quickly on an international scale.
Quantum Partners exclusively advised the shareholders of LARALAB GmbH on this M&A transaction.
About LARALAB
LARALAB GmbH is a Munich-based software startup focusing on AI-based cardiological image analysis. With heart.ai, LARALAB offers the world’s first fully automated solution for the preliminary screening of structural heart procedures (including TAVR/TMTT).
About Abbott Laboratories
Abbott is a US-based, publicly traded pharmaceutical company with over 100,000 employees worldwide. Among other things, the company is one of the leading providers of structural heart therapies with a broad portfolio of transcatheter and surgical solutions.
About Quantum Partners
Quantum Partners GmbH, headquartered in Munich, is a specialized corporate finance advisor that supports clients in company transactions as well as in finding financing.
